New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
14:44 EDTSCMPSucampo issues statement regarding AADPA meeting's vote
Sucampo Pharmaceuticals issued the following statement regarding the Anesthetic and Analgesic Drug Products Advisory Committee meeting's vote: "As a chloride channel activator, AMITIZA has a different mechanism of action than the peripherally acting mu-opioid receptor antagonists and is approved by the U.S.FDA to treat opioid induced constipation. AMITIZA has been prescribed over eight million times over more than eight years and has a well-tolerated safety profile, with no cardiovascular precautions or warnings. FDA did not require Sucampo to reevaluate our clinical data for cardiovascular risks, as they did for the PAMORAS, and AMITIZA was therefore not a participant in this week's Advisory Committee," said Peter Greenleaf, CEO of Sucampo. "We believe the outcome of today's Advisory Committee further demonstrates the FDA's awareness that safety, specifically the potential cardiovascular safety associated with the PAMORAS class of compounds, is paramount in assessing alternative therapies for OIC, which is a severe condition that affects 40-80 percent of the estimated 250 million patients who receive prescriptions for opioids each year for non-cancer pain. OIC is still widely under-identified and under-managed, and we believe that potential new entrants to the market can help increase overall awareness of the condition. We remain committed to maximizing AMITIZA's potential and to bringing it to physicians and patients worldwide for the treatment of OIC."
News For SCMP From The Last 14 Days
Check below for free stories on SCMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
16:40 EDTSCMPSucampo announces exclusive manufacturing, supply agreement for Lubiprostone
Sucampo Pharmaceuticals (SCMP) announced that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement, or EMSA, with its manufacturing and development partner, R-Tech Ueno, for clinical and commercial supplies of AMITIZA, or lubiprostone, in most global markets. Under the new EMSA, Sucampo receives a new, lower price for certain components of or finished product of lubiprostone globally, except for the U.S. and Canada until the collaboration and license agreement with Takeda Pharmaceutical Company (TKPYY), expires in December 31, 2020, and except for Japan until the manufacturing and supply agreement for Japan expires or certain material circumstances occur. Additionally, under the EMSA Sucampo has the right to qualify a back-up supplier for lubiprostone in expanded circumstances, such as an authorized generic, additional formulations, and/or inability to supply product in certain circumstances, among others. The new EMSA supersedes the current manufacturing and supply agreements with R-Tech except in those situations noted above and is effective as of January 1.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use